Jue Pu
Direttore/Membro del Consiglio presso LEPU BIOPHARMA CO., LTD.
Patrimonio netto: 59 M $ in data 31/05/2024
Posizioni attive di Jue Pu
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| LEPU BIOPHARMA CO., LTD. | Direttore/Membro del Consiglio | 22/04/2020 | - |
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | 01/10/2018 | - |
Storia della carriera di Jue Pu
Precedenti posizioni note di Jue Pu
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CG ONCOLOGY, INC. | Direttore/Membro del Consiglio | 01/03/2019 | 01/10/2023 |
| CG ONCOLOGY, INC. | Direttore/Membro del Consiglio | 01/01/2010 | 01/01/2018 |
| Fondatore | 01/01/2010 | 01/01/2018 |
Formazione di Jue Pu
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
| Stanford University | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Cina | 2 |
Posizioni
| Director/Board Member | 4 |
| Founder | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CG ONCOLOGY, INC. | Health Technology |
| LEPU BIOPHARMA CO., LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Jue Pu
- Esperienza
